Cutia Therapeutics
Cutia Therapeutics is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies in the field of oncology and autoimmune diseases.
Business. Cutia Therapeutics (2487.HK) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The company is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic mix are not available.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Cutia Therapeutics (2487.HK) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in pharmaceuticals and medical research. The company is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic mix are not available.
Cutia Therapeutics has a market capitalization of CNY 1.45 billion, with a current market price of CNY 4.00 per share, and no dilution risk based on the current share count of 363.37 million shares outstanding. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability metrics are not available in the current dataset, and no direct comparison to industry_config preferred metrics or cohort medians can be made. However, the current analyst price target of CNY 11.22 suggests a potential upside of 180.5% from the current market price.
Cutia Therapeutics' revenue concentration and geographic exposure are not disclosed in the available data. The company's business is primarily focused on the development of innovative therapies, with no specific segments or geographic regions highlighted in the current dataset.
The company's growth trajectory is not quantified in the current dataset, but the analyst estimates indicate a strong buy consensus with a mean recommendation of 1.50, suggesting positive expectations for the company's future performance.
The company's risk assessment indicates low dilution potential, with no near-term pressure expected. However, the absence of balance-sheet data limits the ability to assess liquidity risk comprehensively.
Recent events and filings are not detailed in the current dataset, but the company's current price target and analyst recommendations suggest a positive outlook among market participants.
- Cutia Therapeutics is a biopharmaceutical company with a focus on oncology and autoimmune disease therapies.
- The company has a current market price of CNY 4.00 and a market capitalization of CNY 1.45 billion.
- Analysts have a strong buy consensus with a mean price target of CNY 11.22, indicating a potential upside of 180.5%.
- The company's liquidity risk could not be assessed due to the absence of balance-sheet data.
- Cutia Therapeutics has low dilution risk, with no near-term pressure expected.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥336.2M, +20,2% YoY; Operating income +21,9% YoY.
- ▍Revenue ¥336.2M, +20,2% YoY
- ▍Operating income +21,9% YoY
- ▍Net income +21,6% YoY
- ▍Free cash flow +25,4% YoY
- ▍Net margin -101.2%
Revenue ¥279.6M, +103,2% YoY; Operating income +78,4% YoY.
- ▍Revenue ¥279.6M, +103,2% YoY
- ▍Operating income +78,4% YoY
- ▍Net income +77,9% YoY
- ▍Free cash flow +79,0% YoY
- ▍Net margin -155.1%
Revenue ¥137.6M, +1 110,8% YoY; Operating income −253,6% YoY.
- ▍Revenue ¥137.6M, +1 110,8% YoY
- ▍Operating income −253,6% YoY
- ▍Net income −253,3% YoY
- ▍Free cash flow −194,1% YoY
- ▍Net margin -1426.9%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,01 |
| Revenue | —no estimate | —no estimate | 584,2M CNY |
| Operating income | —no estimate | —no estimate | -9,5M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Cutia Therapeutics Market data — financials · 2026-05-26
- Cutia Therapeutics Market data — analyst estimates · 2026-05-26